Long-Term Outcome and Role of Biology within Risk-Adapted Treatment Strategies: The Austrian Neuroblastoma Trial A-NB94

• Published in: Cancers 2021-02, Vol.13 (3), p.572
• Main Authors: Fiedler, Stefan, Ambros, Inge M, Glogova, Evgenia, Benesch, Martin, Urban, Christian, Mayer, Marlene, Ebetsberger-Dachs, Georg, Bardi, Edit, Jones, Neil, Gamper, Agnes, Meister, Bernhard, Crazzolara, Roman, Amann, Gabriele, Dieckmann, Karin, Horcher, Ernst, Kerbl, Reinhold, Brunner-Herglotz, Bettina, Ziegler, Andrea, Ambros, Peter F, Ladenstein, Ruth
• Format: Article
• Language: English
• Subjects: Age; Autografts; Biomarkers; Chemotherapy; Clinical trials; Immunotherapy; Infants; Monoclonal antibodies; Neuroblastoma; Patients; Population; Radiation; Stem cells; Surgery; Tumors
• ISSN: 2072-6694; 2072-6694
• DOI: 10.3390/cancers13030572

We evaluated long-term outcome and genomic profiles in the Austrian Neuroblastoma Trial A-NB94 which applied a risk-adapted strategy of treatment (RAST) using stage, age and amplification (MNA) status for stratification. RAST ranged from surgery only to intensity-adjusted chemotherapy, single or multiple courses of high-dose chemotherapy (HDT) followed by autologous stem cell rescue depending on response to induction chemotherapy, and irradiation to the primary tumor site. Segmental chromosomal alterations (SCAs) were investigated retrospectively using multi- and pan-genomic techniques. The A-NB94 trial enrolled 163 patients. Patients with localized disease had an excellent ten-year (10y) event free survival (EFS) and overall survival (OS) of 99 ± 1% and 93 ± 2% whilst it was 80 ± 13% and 90 ± 9% for infants with stage 4S and for infants with stage 4 non-MNA disease both 83 ± 15%. Stage 4 patients either >12 months or ≤12 months but with MNA had a 10y-EFS and OS of 45 ± 8% and 47 ± 8%, respectively. SCAs were present in increasing frequencies according to stage and age: in 29% of localized tumors but in 92% of stage 4 tumors ( < 0.001), and in 39% of patients ≤ 12 months but in 63% of patients > 12 months ( < 0.001). RAST successfully reduced chemotherapy exposure in low- and intermediate-risk patients with excellent long-term results while the outcome of high-risk disease met contemporary trials.